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Genetic polymorphisms of the renin-angiotensin system and the
outcome of focal segmental glomerulosclerosis in children.
Background. The clinical course of primary focal segmental
glomerulosclerosis (FSGS) in children is variable, with some
patients having a much more rapidly progressing course than
others. The purpose of our study was to compare the frequency of
three polymorphisms of the renin-angiotensin system (RAS) in
children with FSGS with that in healthy controls of matching
ethnic groups, and to determine whether the clinical outcome of
FSGS was associated with different RAS genotypes.
Methods. Three RAS genotypes were examined in 47 Jewish
and Arab children with biopsy-proven primary FSGS and in a
large control group: the ACE insertion/deletion polymorphism in
intron 16, the M235T mutation in the angiotensinogen gene, and
the A1166C in the angiotensin II type 1 receptor gene (AT1R).
Results. Arab patients showed a greater tendency towards
progressive renal disease than their Jewish counterparts (12 of 21
vs. 9 of 26, P 5 0.05) and were less likely to achieve remission (3
of 21 vs. 11 of 26, P , 0.04), despite similar clinical presentation,
medical management and follow-up. The RAS allele prevalence
was similar among patients and controls of matching ethnic
backgrounds, and no difference in allele frequency was found
between Arabs and Jews. Homozygotes for the ACE insertion
genotype (II) were significantly less likely to have progressive
renal disease than patients with the other genotypes (ID and DD;
0 of 6 vs. 21 of 41; P , 0.022). The other RAS polymorphisms
were not associated with variations in the clinical course of
childhood FSGS.
Conclusions. Homozygosity for the ACE insertion allele may
have a protective effect in children with FSGS and can serve as a
positive prognostic indicator at diagnosis. The D allele may exert
a detrimental dominant effect on outcome. Neither the ACE gene
polymorphism nor the other RAS polymorphisms studied are
associated with disease prevalence. The AT1R and angiotensino-
gen gene polymorphisms are not associated with progression of
renal disease in FSGS. Ethnic differences in the clinical course of
the disease are not linked to these polymorphisms.
Focal segmental glomerulosclerosis (FSGS) is one of the
most severe acquired renal diseases in children. Its clinical
presentation is generally that of a steroid resistant ne-
phrotic syndrome with up to two thirds of the patients
progressing to end-stage renal failure (ESRF) within six to
eight years [1–4]. The clinical course varies among differ-
ent ethnic groups. For example, the progression of FSGS is
more relentless in American children of African or His-
panic origin, in whom a higher prevalence of the disease
was also noted [4]. The diagnosis of FSGS is histopatho-
logical, with the characteristic initial finding of partial
sclerosis of individual but not all glomeruli, slowly progress-
ing to generalized nephrosclerosis [1]. Secondary FSGS
may occur in diabetic nephropathy, heroin abuse, HIV
infection, reflux nephropathy and morbid obesity [1, 2,
5–9]. The focus of this study is on primary FSGS.
Corticosteroid therapy, the mainstay of treatment in
other forms of nephrotic syndrome in children, has yielded
disappointing results in FSGS. Recent trials showed that
with the use of long-term corticosteroid therapy, cyclospor-
ine and/or alkylating agents it was possible to induce
remission in some patients. Many patients relapse when
treatment is stopped [2, 3]. Clinically, the best prognostic
indicator is whether or not remission can be induced. Only
a small minority of patients who enter remission will
experience a decline in renal function [2]. The pathogenesis
of FSGS remains obscure, as are the mechanisms respon-
sible for the gradual decline in renal function. Attempts to
identify distinct morphological subgroups predictive of
progression to renal failure in children with FSGS have
failed [10].
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Several factors point to the possible role of genetic
influences on the outcome of FSGS in children. These
include the variable clinical course, the higher prevalence
of the disease in different ethnic groups [4] and the familial
forms of FSGS [11].
The renin-angiotensin system (RAS) has been consid-
ered one of the probable pathophysiologic mechanisms
governing disease progression. Genetic polymorphisms of
the various components of the RAS have been associated
with the clinical course of several disease states in adults.
The RAS polymorphism studied most extensively is a
deletion or insertion of a 287 bp fragment in intron 16 of
the angiotensin converting enzyme (ACE) gene [12]. The
DD genotype has been associated with an increased risk of
myocardial infarction and left ventricular hypertrophy [13,
14] and with declining renal function in patients with
diabetes mellitus and IgA-nephropathy [15–18]. Other
polymorphisms studied include the A1166C mutation in
the angiotensin II type 1 receptor (AT1R) and the M235T
mutation in the angiotensinogen gene [19–26]. In view of
the impact of genetic polymorphisms of the RAS on the
course of other chronic glomerulopathies, it is possible that
a similar association exists in FSGS. The object of this study
was to evaluate the association between genetic polymor-
phisms of the RAS and the prevalence and course of FSGS
in our young patient population.
METHODS
Patients and control subjects
Forty-seven patients, aged five months to 15 years at the
time of diagnosis (20 boys, 27 girls), were recruited from
the pediatric renal units of eight hospitals in Israel. All
patients had biopsy-proven primary FSGS and presented
with a full blown nephrotic syndrome. Patients in remission
or with stable renal function were included if there was at
least a five year follow-up. The ethnic distribution was Arab
(N 5 21) and Jewish (N 5 26). After informed consent for
the genetic studies was obtained from the parents of all
patients, blood samples were obtained for DNA analysis.
The study was approved by the institutional review board
(Helsinki Committee) of the Shaare Zedek Medical Cen-
ter.
The patients were classified as having either stable renal
function (N 5 26) or declining renal function (N 5 21).
Declining renal function was defined as doubling of serum
creatinine from the onset of the nephrotic syndrome, to the
time of the study. This latter group included patients on
renal replacement therapy (chronic dialysis or after renal
transplantation). Patients were also classified as having
severe proteinuria (N 5 33) or being in remission (N 5 14).
Proteinuria was defined as urinary protein excretion ex-
ceeding 40 mg/m2/hr. Patients with urinary protein less than
4 mg/m2/hr and stable renal function were considered to be
in remission.
The control group consisted of unrelated healthy volun-
teers, recruited from the hospital staff and from three
institutions of higher learning in the vicinity. The control
subjects were 18 to 55 years of age, without hypertension,
renal or cardiac disease, had no family history of renal
disease and none received treatment with ACE inhibitors
or other antihypertensive medications. The ethnic distribu-
tion among the members of the control group was Jewish
Ashkenazi origin (N 5 56), Sephardic (including individu-
als of North-African, Asian and Yemenite origin; N 5 116)
and Arabs (N 5 44). This large group of healthy subjects
enabled us to study the distribution of the various allelic
polymorphisms of the RAS in individuals of different
ethnic backgrounds in Israel.
Angiotensin converting enzyme genotype determination
Genomic DNA was extracted from whole blood, col-
lected in tubes containing EDTA, as described previously
[27], and suspended in 10 mM Tris-HCl, 1 mM EDTA, pH
8. To determine the ACE genotype of the patients, poly-
merase chain reaction (PCR) was used to amplify a DNA
fragment in intron 16 of the ACE gene [15, 18]. Primers
flanking the insert sequence were 59-CTGGAGAC-
CACTCCCATCCTTTCT and 59-GATGTGGCCA- TCA-
CATTCGTCAGAT. Polymerase chain reaction (PCR)
amplification was performed in a 20 ml reaction containing
1 ml genomic DNA, 50 mM KCl, 1 mM MgCl2, 10 mM
Tris-HCl pH 9, 0.1% Triton X-100, 200 mM deoxynucle-
otide triphosphates, 1 mM primers and 0.5 unit of thermo-
stable DNA polymerase. Thermocycling in Robocycler
(Stratagene) consisted of 10 minutes of denaturation at
94°C, followed by 30 cycles of one minute at 94°C, anneal-
ing one minute at 63°C, extension of two minutes at 72°C
and final extension of five minutes at 72°C. This reaction
yields PCR products of ;490 bp and ;190 bp correspond-
ing to the insertion (I) and deletion (D) alleles, respec-
tively. These were detected on an ethidium bromide stained
2% agarose gel.
To increase the specificity of DD genotyping, in light of
the preferential amplification of the D allele in comparison
to the I allele, a second PCR reaction was performed on all
samples using an insert specific primer pair, 59-TGGGAC-
CACAGC-GCCCGCCACTAC and 59-TCGCCAGC-
CCTCCCATGCCCATAA [15, 18]. The amplification was
performed in a 15 ml reaction mixture containing 1 ml
genomic DNA, 50 mM KCl, 1 mM MgCl2, 10 mM Tris-HCl
pH 9, 0.1% Triton X-100, 200 mM deoxynucleotide triphos-
phates, 1 mM primers and 0.5 unit of thermostable DNA
polymerase. Thermocycling consisted of five minutes of
denaturation at 94°C, followed by 30 cycles of 30 seconds at
94°C, annealing 45 seconds at 67°C, extension of two
minutes at 72°C and final extension of five minutes at 72°C.
This reaction yields a 335 bp product only in samples
containing the insertion. Amplification of the DD genotype
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does not yield any product. The 335 bp product was
detected on an ethidium bromide stained 2% agarose gel.
Angiotensinogen genotype
To determine the angiotensinogen M235T genotype, a
DNA fragment on exon 2 of the gene was amplified using
the following primers: 59-TGACAGGATGGAAGACTG-
GCTGCTCCCTGC and 59-AGCAGAGAGGTTTGCCT-
TACCTTG [22]. The reaction was performed in a final
volume of 50 ml containing 2 ml genomic DNA, 50 mM KCl,
1 mM MgCl2, 10 mM Tris-HCl pH 9, 0.1% Triton X-100, 200
mM deoxynucleotide triphosphates, 0.5 mM primers and 1
unit of thermostable DNA polymerase. Thermocycling
consisted of five minutes of denaturation at 94°C, followed
by 30 cycles of one minute at 97°C, annealing 40 seconds at
62°C, extension of one minute at 72°C and final extension
of five minutes at 72°C. The primer pair create a new
restriction endonuclease site in the presence of the specific
mutation, where there is a base substitution of T3C at
nucleotide 704 on exon 2. This base substitution causes a
replacement of methionine by threonine in the protein.
The PCR products of 104 bp were incubated overnight with
MspI restriction endonuclease at 37°C. MspI digestion of
the homozygote C-type variant of M235T produces 2
fragments of 31 bp and 73 bp. The heterozygotes show
three bands, whereas the T-type variant is not digested and
shows only the 104 bp band. These were detected on 3%
Nusieve agarose gel stained with ethidium bromide.
Angiotensin II receptor type 1 genotype
Determination of angiotensin II type 1 receptor A1166C
genotype was performed by amplifying a DNA fragment,
encompassing the polymorphism, using the following prim-
ers: 59-AATGCTTGTAGCCAAAGTCACCT and 59-
GGCTTTGCTTTGTCT- TGTTG [15]. PCR amplification
was obtained using 30 ml reaction containing 1.5 ml
genomic DNA, 50 mM KCl, 1 mM MgCl2, 10 mM Tris-HCl
pH 9, 0.1% Triton X-100, 200 mM deoxynucleotide triphos-
phates, 1 mM primers and 0.5 unit of thermostable DNA
polymerase. Thermocycling consisted of two minutes of
denaturation at 94°C, followed by 40 cycles of one minute
at 94°C, annealing one minute at 60°C, extension of two
minutes at 72°C and final extension of 10 minutes at 72°C.
The PCR products of 850 bp were incubated overnight with
the restriction endonuclease DdeI at 37°C, which cuts the
product into two pieces, 600 and 250 bp long. An additional
DdeI recognition site is created in the C-type variant, at
nucleotide 1166, which is found in the 250 bp fragment.
Thus the homozygote CC produces three bands (600, 140
and 110 bp long), the homozygote AA produces two bands
(600 and 250 bp long), and the heterozygote produces all
four bands. These were detected on 3% agarose gel stained
with ethidium bromide.
Statistical analysis
Clinical data are reported as mean 6 SD. Statistical
analyses were performed on the actual number of the
genotypes/alleles and not on their relative percentage.
Quantitative data were compared with the Student’s t-test.
Genotypes, alleles and other qualitative data were analyzed
by the chi squared and Fisher’s exact test.
RESULTS
Study population
During the collection of the data from children with
FSGS, it became clear that the clinical outcome was
different in Jewish compared to Arab patients. The char-
acteristics of these two groups are summarized in Table 1.
No differences between the two groups were found in age
at onset, gender, incidence of hypertension, duration of
follow up and treatment modalities. Yet, Arab patients
were significantly less likely to achieve remission (3 of 21 vs.
11 of 26 for Arab and Jewish patients, respectively, P ,
0.04) and were more likely to have declining renal function
(12 of 21 vs. 9 of 26, P 5 0.05).
ACE polymorphism
Prevalence of disease. In the entire group of children with
FSGS, the frequencies of the II, ID and DD genotypes of
the ACE gene were 12.8%, 42.5% and 44.7%, respectively.
The distribution was in Hardy-Weinberg equilibrium and
was not different from the genotype frequencies that we
observed in the total healthy control population (Table 2),
nor among specific ethnic subgroups, namely Jews of
Ashkenazi origin, Jews originating in North Africa, Asia or
Table 1. Patient characteristics
Arab
(N 5 21)
Jewish
(N 5 26) P value
Presentation
Age years 5.9 6 4.2 6.5 6 4.8 NSa
Male sex 8 (38) 12 (46) NSb
Nephrotic range proteinuria 21 (100) 26 (100) NSb
Serum creatinine mg/dl 0.66 6 0.13 0.62 6 0.12 NSa
Hypertension 8 (38) 9 (35) NSb
Treatment
Corticosteroids 21 (100) 26 (100) NSb
Cyclosporine 9 (43) 7 (29) NSb
Cyclophosphamide 9 (43) 17 (65) NSb
Follow up months 58.31 6 53.6 75.12 6 71.0 NSa
Outcome
Serum creatinine (mg/dl) 4.76 6 0.87 2.33 6 0.80 ,0.05a
Nephrotic-range proteinuria 18 (86) 15 (58) ,0.04c
Declining renal function 12 (57) 9 (35) 50.05b
Renal replacement therapy 8 (44) 6 (25) NSb
Time to RRT (months) 44.1 6 12 37 6 17 NSa
Remission 3 (14) 11 (46) ,0.04c
Values are number of patients, with percentages in parentheses, unless
otherwise indicated RRT is renal replacement therapy.
a Student’s t-test
b chi squared
c Fisher’s exact test
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Yemen, or Arabs (data not shown). This suggests that none
of the genotypes studied is a risk factor for developing
FSGS.
Progression of renal disease. To evaluate the correlation
between ACE polymorphism and the course of FSGS, we
compared the allelic distribution in patients with declining
renal function to its distribution in children with preserved
renal function. Patients homozygous for the I allele had a
much better prognosis than patients with the D allele. All
children with the II genotype had conserved renal function,
compared to only 20 of 41 with the ID and DD genotypes
(P , 0.022, Fisher’s exact test; Fig. 1). The outcome of
heterozygotes for the D allele was similar to that of
homozygotes, a finding suggesting that the D allele has a
dominant and adverse effect on renal function of children
with FSGS. A similar trend was noted when remission was
compared to persistent proteinuria. Two thirds of the
children with the II genotype were in remission compared
to 24% of individuals with the D allele (P , 0.055, Fisher’s
exact test; Fig. 1). Despite the higher rate of progressive
disease among Arab patients, no differences were found in
the ACE genotype frequencies between Arab and Jewish
patients. Moreover, in the subgroup of Arab children, all
patients with the II genotype were in complete remission,
whereas those with the D allele were all proteinuric (P ,
0.001, Fisher’s exact test). Similarly, Arab patients with the
II genotype were more likely to maintain stable renal
function compared to the D allele (P , 0.06, Fisher’s exact
test).
Other RAS-associated polymorphisms
We also performed an analysis of the genotype and allele
frequencies of the angiotensin II type 1 receptor (AT1R)
A1166C polymorphism and the angiotensinogen M235T
mutation, in patients and controls of matching ethnic
backgrounds. No differences were found between the pa-
tient and control groups in the frequencies of these poly-
morphisms (Table 3). Furthermore, no association was
found between continued proteinuria or unstable renal
function and a particular genotype of the AT1R A1166C
polymorphism or the angiotensinogen M235T mutation
(Fig. 2). Thus, it would seem that neither the AT1R
A1166C nor the angiotensinogen M235T mutations are
independent risk factors for FSGS or affect its clinical
course. In addition, these two polymorphic markers did not
interact with the ACE I/D polymorphism in determining
susceptibility to disease or its progression.
DISCUSSION
Our study of Jewish and Arab children with biopsy-
proven primary FSGS demonstrates that the course of the
disease varies greatly between these two populations. Al-
though these two groups did not differ in age, gender,
Table 2. Genotypes (frequencies) of the angiotensin converting enzyme
I/D polymorphism in children of various ethnic background with FSGS
compared to healthy controls
ACE
genotype
Patients
Controls
(N 5 216)
P
value
Jewish
(N 5 26)
Arab
(N 5 21)
Total
(N 5 47)
II 3 (11.5) 3 (14.3) 6 (12.8) 22 (10.2) NSa
ID 13 (50.0) 7 (33.3) 20 (42.5) 110 (50.9) NSa
DD 10 (38.5) 11 (52.4) 21 (44.7) 84 (38.9) NSa
a Chi squared
Fig. 1. Angiotensin converting enzyme (ACE) insertion/deletion (I/D)
genotypes and the course of renal disease in children with focal segmental
glomerulosclerosis (FSGS). (A) Symbols are: (M) patients with stable
renal function at the time of the study; (u) patients with declining renal
function (II compared with ID1DD, P , 0.022, Fisher’s exact test). (B)
Symbols are: (M) patients in remission (urinary protein , 4 mg/m2/hr and
stable renal function) at the time of study; (u) patients with nephrotic-
range proteinuria (II compared with ID 1DD P , 0.055, Fisher’s exact
test).
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symptoms at onset, length of follow-up or treatment mo-
dalities, the rate of remission was threefold greater in
Jewish patients, and the rate of declining renal function was
significantly lower in Jewish compared to Arab patients.
The patients who progressed to ESRF, both Jews and
Arabs, did so in an average time of just over three years.
The incidence of hypertension, a factor that may accelerate
the progression of renal failure, was similar in both groups
and cannot account for the differential outcome. Ethnic
differences in the course of FSGS have been previously
reported in the USA. African-American and Hispanic
children have a high prevalence of an aggressive form of
FSGS, which has a bad outcome, meaning a high percent-
age of ESRD [4, 28]. In fact, Schulman, Vanisco and
Kaplan may have identified two distinct clinical entities of
FSGS that share common histological characteristics [28].
White patients present at a younger age and seem to have
a more benign course than non-white patients. Our study
does not support an increased prevalence among one
specific ethnic group, but certainly points to a more severe
prognosis in Arab children.
Analyses of the genotypes of the RAS in our children
with FSGS and the control subjects of matching ethnic
groups showed no significant difference in the genotype
distribution of the insertion/deletion polymorphism of the
angiotensin converting enzyme, of the AT1R gene muta-
tion A1166C, or of the angiotensinogen gene mutation
M235T. None of these genetic variations seem to confer a
susceptibility to the disease. Similar results were achieved
when the relative frequencies of the various RAS genetic
polymorphisms were studied in other models of primary
progressive renal disease [15–17]. In contrast, in renal
involvement of systemic diseases like diabetic nephropathy,
it has recently been shown that the ACE I/D polymorphism
is associated with both the susceptibility to disease as well
as its progression towards renal failure [29].
Our study indicates that homozygosity for the ACE I
allele in children with FSGS is associated with a good
outcome. In these children renal function is preserved and
they are more likely to acquire remission of their nephrotic
syndrome. The D allele has a dominant effect and is
associated with progressive disease. The II genotype can
therefore serve as a positive prognostic indicator at diag-
nosis in children with nephrotic syndrome due to primary
FSGS. A similar pattern has been observed in patients with
insulin-dependent diabetes mellitus [29]. Individuals with
the II genotype have been shown to have lower plasma and
cellular ACE levels than those with the DD or ID geno-
types [12, 30]. The present data are consistent with the
hypothesis that constitutive levels of angiotensin II seem to
Table 3. Genotypes (frequencies) of the AT1R A1166C polymorphism
and the angiotensinogen M235T polymorphism in children with FSGS
and healthy controls
Patients
(N 5 42)
Controls
(N 5 216)
AA 28 (67.4) 124 (57.4)
AC 14 (32.6) 79 (36.6)
CC 0 13 (6.0)
P 5 NS (chi squared)
MM 11 (26.8) 81 (38.6)
MT 20 (48.8) 85 (40.5)
TT 10 (24.4) 44 (20.9)
P 5 NS (chi squared)
For the antiotensinogen mutation analysis, only 41 patients and 210
controls were available.
Fig. 2. The AT1R A1166C and the angiotensinogen M235T genotypes
and the clinical course of children with FSGS. (A) Symbols are: (M)
patients with stable renal function at the time of the study; (u) patients
with declining renal function. P 5 nonsignificant (chi squared). (B)
Symbols are: (M) patients in remission (urinary protein , 4 mg/m2/hr and
stable renal function) at the time of study; (u) patients with nephrotic-
range proteinuria. P 5 nonsignificant (chi squared).
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be critical for the susceptibility of the glomerular circula-
tion to external injury, and hence, for affecting the progres-
sion of renal diseases [31].
We found no correlation between ethnicity and ACE I/D
genotype, despite the difference in the course of disease.
The clinical course among Jewish patients was similar to
that described in Caucasian children in the United States
[1–3], whereas the Arab patients followed a course resem-
bling the one described in African-Americans [4]. The
reason for this clinical variability among different ethnic
groups has yet to be elucidated. Studies of the ACE I/D
genotype frequencies in different ethnic groups have shown
that the D allele frequency is higher in African Americans
[32] than in Caucasian [13] and Japanese [17] populations.
Although it is possible that the clinical differences between
African American and Caucasian children with FSGS may
be associated with differences in I/D allele frequencies, this
has yet to be proven. In our study population the ACE I/D
genotype frequencies were similar in Jewish and Arab
patients. The poor prognosis of FSGS in Arab children in
Israel is not associated with an increased prevalence of any
RAS genotype. We found the II genotype to be a positive
prognostic factor in children with FSGS from both ethnic
groups. This positive correlation was found to be even
stronger when applied to the subgroup of Arab patients.
This implies that the impact of the II genotype on the
course of FSGS is stronger than ethnicity in our group of
patients.
Several mechanisms have been implicated as modulators
of progression of renal disease. One theory that has been
extensively investigated is the hyperfiltration theory. Re-
duction in renal mass leads to hypertrophy of the remaining
nephrons, hyperperfusion and intraglomerular hyperten-
sion, resulting in segmental glomerulosclerosis associated
with proteinuria and decreased renal function [33, 34]. Two
observations have linked this mechanism to FSGS. Fogo
and colleagues pointed out that glomerulomegaly predicted
subsequent glomerulosclerosis in patients with minimal
change nephrotic syndrome [35]. More recently, it has been
suggested that patients with FSGS have fewer, though
larger glomeruli than patients with minimal change ne-
phrotic syndrome [36]. Since Black individuals have fewer
glomeruli than Caucasians [37], this might in part account
for the relatively high incidence and the more severe course
of FSGS among African-Americans. Since this aspect has
never been studied in Jews and Arabs its applicability
remains uncertain.
Proteinuria has been found to be an independent factor
affecting progression of renal disease. In glomerular dis-
ease, proteinuria, especially in the nephrotic range, is
associated with faster deterioration in renal function, re-
gardless of the initial diagnosis [38]. All our patients had
nephrotic range proteinuria at presentation, but the Arab
children were less likely to enter remission, and therefore
remained proteinuric for longer periods of time than their
Jewish counterparts. This may explain in part why deteri-
oration in renal function was more common among Arab
children with FSGS. Why proteinuria was more likely to
persist in the Arab patients remains unresolved.
It is unlikely that the difference in the course of disease
between Jewish and Arab children with FSGS can be
attributed to selection bias. Our patients were recruited
from eight major hospitals in Israel, and we estimate that
they constitute the vast majority of children with FSGS in
the country. Young Arab patients from within the area
governed by the Palestinian Authority joined the study
either through the only pediatric nephrology unit in the
West Bank, or were referred to the Shaare Zedek Pediatric
Nephrology Unit for treatment. By including only biopsy
proven cases, we may have excluded patients with FSGS
presenting as a corticosteroid responsive nephrotic syn-
drome, who were not biopsied. This, however, is a limita-
tion of any study of this disease, in any ethnic group.
FSGS refers to a specific renal histological finding; it is
not a disease entity [39]. The term “idiopathic” or “prima-
ry” only reflects our present ignorance in regard to etiology
and pathogenesis, and as time passes it will probably
become obsolete. At this point in time it is difficult to
precisely delineate the mechanisms that underlie the pro-
gressive nature of a disease such as FSGS in children.
Progression of renal disease is the result of an interaction
between genetic and environmental factors that individu-
ally impact upon the phenotype, and together influence the
ultimate clinical outcome. The RAS is only one of the
mechanisms affecting progression [40–42]. When a more
powerful mechanism is imposed, the contribution of the
RAS is minimized and renal deterioration ensues rapidly.
The ACE DD genotype has been linked to a progressive
course in IgA nephropathy [15, 17] and in diabetic ne-
phropathy [18]. In these two disease entities the pattern of
progression of the renal disease is one of slow deteriora-
tion, whereas in FSGS it is generally far more rapid. We
therefore speculate that the RAS has a pivotal role in
diseases with slow progression, which are amenable to
treatment with ACE inhibitors that can attenuate the rate
of decline in renal function [43–45]. We believe that the
role of ACE inhibitors should be studied prospectively in
children with FSGS, with special emphasis on the genetic
makeups of the patients.
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